Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?Thakar MS; Forman SJHematology Am Soc Hematol Educ Program 2009[]; ä (ä): 414-8A 35-year-old male with a FLT3(+) AML underwent allogeneic peripheral blood stem cell transplant using a myeloablative non-total body irradiation (TBI) conditioning regimen from his HLA-matched sibling donor. Following transplantation, he developed grade II acute graft-versus-host disease (GVHD) that resolved with increasing immunosuppression. The medications were subsequently discontinued, and he did not develop any evidence of chronic GVHD. Eighteen months after transplant, while off all immunosuppression, he developed fatigue and a blood count showed circulating blasts consistent with relapse of his disease. Among the various therapeutic questions is whether there is a role for a second allogeneic transplant to treat his disease and if so, at what time, with what conditioning, and with which type of donor.|*Hematopoietic Stem Cell Transplantation[MESH]|*Practice Guidelines as Topic[MESH]|Acute Disease[MESH]|Adult[MESH]|Evidence-Based Medicine[MESH]|Graft vs Host Disease/drug therapy/etiology[MESH]|Humans[MESH]|Immunosuppressive Agents/therapeutic use[MESH]|Leukemia, Myeloid/*surgery[MESH]|Male[MESH]|Recurrence[MESH]|Reoperation[MESH]|Tissue Donors[MESH]|Transplantation, Homologous[MESH]|fms-Like Tyrosine Kinase 3/analysis[MESH] |